文献速递消化、代谢与肾脏急症心脑血管急症

美国慢性肾脏病退伍军人他汀使用、死亡率与主要不良心血管事件

Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease.
PubMed 文献 · JAMA Netw Open · 2023-12-01
一句话结论在65岁以上、CKD 3–4期且无ASCVD的退伍军人中,启动他汀与全因死亡风险较低相关(HR 0.91),但与MACE无显著相关(HR 0.96)。

该研究采用目标试验模拟设计,利用退伍军人事务部、Medicare和Medicaid关联数据,纳入2005–2015年新诊断中度CKD(3或4期)、年龄>65岁、无既往ASCVD且未使用他汀的退伍军人。分析共纳入14 828人,经重叠权重调整后比较他汀启动者与非启动者的结局。他汀启动与全因死亡风险降低相关(HR 0.91,95%CI 0.85–0.97),与MACE无显著相关(HR 0.96,95%CI 0.91–1.02)。作者认为结果需在随机临床试验中确认。

要点

  • 在>65岁、CKD 3–4期且无ASCVD的退伍军人中,启动他汀与全因死亡风险较低相关(HR 0.91,95%CI 0.85–0.97)。
  • 他汀启动与MACE无显著相关(HR 0.96,95%CI 0.91–1.02)。
  • 预设亚组分析结果与主要结果一致。
  • 该研究为目标试验模拟设计,作者认为结果需在随机临床试验中确认。

适用人群与场景

  • 美国退伍军人,年龄>65岁,2005–2015年新诊断中度CKD(3或4期),诊断后5年内,无既往ASCVD或他汀使用,且试验基线前1年内至少1次临床就诊。

诊断标准与关键阈值

  • CKD分期为3期或4期(中度CKD)。
  • 无既往ASCVD。
  • 无既往他汀使用。

研究设计与关键结果

  • 研究设计:队列研究,采用目标试验模拟设计,嵌套试验结合倾向权重方法,使用退伍军人事务部、Medicare和Medicaid关联数据,随访至2017年12月31日。
  • 纳入14 828名退伍军人,CKD诊断时平均(SD)年龄76.9(8.2)岁,14 616人(99%)为男性,10 539人(72%)为白人,2568人(17%)为黑人。
  • 扩展至人-试验并在每个基线评估合格性后,非他汀启动者共151 243个人-试验(14 685人),他汀启动者共2924个人-试验(2924人)。
  • 通过重叠权重进行倾向评分调整并采用非参数自举法,实现协变量平衡,平均(SD)随访3.6(2.7)年。
  • 他汀启动者与非启动者相比,全因死亡风险比HR 0.91(95%CI 0.85–0.97)。
  • 他汀启动者与非启动者相比,MACE风险比HR 0.96(95%CI 0.91–1.02)。
  • 预设亚组分析结果与主要结果一致。

证据类型、等级与局限

  • 证据类型:目标试验模拟的队列研究。
  • 局限:作者认为结果需在随机临床试验中确认。

对床旁实践的改变

  • 作者认为,在>65岁、CKD 3–4期且无既往ASCVD的美国退伍军人中,启动他汀与全因死亡风险较低相关,但与MACE无显著相关;结果需在随机临床试验中确认。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There are limited data for the utility of statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) and death in adults with chronic kidney disease (CKD).

OBJECTIVE: To evaluate the association of statin use with all-cause mortality and major adverse cardiovascular events (MACE) among US veterans older than 65 years with CKD stages 3 to 4.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a target trial emulation design for statin initiation among veterans with moderate CKD (stages 3 or 4) using nested trials with a propensity weighting approach. Linked Veterans Affairs (VA) Healthcare System, Medicare, and Medicaid data were used. This study considered veterans newly diagnosed with moderate CKD between 2005 and 2015 in the VA, with follow-up through December 31, 2017. Veterans were older than 65 years, within 5 years of CKD diagnosis, had no prior ASCVD or statin use, and had at least 1 clinical visit in the year prior to trial baseline. Eligibility criteria were assessed for each nested trial, and Cox proportional hazards models with bootstrapping were run. Analysis was conducted from July 2021 to October 2023.

EXPOSURE: Statin initiation vs none.

MAIN OUTCOMES AND MEASURES: Primary outcome was all-cause mortality; secondary outcome was time to first MACE (myocardial infarction, transient ischemic attack, stroke, revascularization, or mortality).

RESULTS: Included in the analysis were 14 828 veterans. Mean (SD) age at CKD diagnosis was 76.9 (8.2) years, 14 616 (99%) were men, 10 539 (72%) White, and 2568 (17%) Black. After expanding to person-trials and assessing eligibility at each baseline, there were 151 243 person-trials (14 685 individuals) of nonstatin initiators and 2924 person-trials (2924 individuals) of statin initiators included. Propensity score adjustment via overlap weighting with nonparametric bootstrapping resulted in covariate balance, with mean (SD) follow-up of 3.6 (2.7) years. The hazard ratio for all-cause mortality was 0.91 (95% CI, 0.85-0.97) comparing statin initiators to noninitiators. The hazard ratio for MACE was 0.96 (95% CI, 0.91-1.02). Results remained consistent in prespecified subgroup analyses.

CONCLUSIONS AND RELEVANCE: In this target trial emulation of statin initiation in US veterans older than 65 years with CKD stages 3 to 4 and no prior ASCVD, statin initiation was significantly associated with a lower risk of all-cause mortality but not MACE. Results should be confirmed in a randomized clinical trial.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Barayev O, Hawley CE, Wellman H, et al. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. JAMA Netw Open. 2023. PMID: 38055276. doi:10.1001/jamanetworkopen.2023.46373

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。